α-Blockers for benign prostatic hyperplasia: The new era

Current Opinion in Urology

Volumn 22, Issue 1, 2012, Pages 7-15

  Lepor, Herbert ^a   Kazzazi, Amir ^a   Djavan, Bob ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blockers; benign prostatic hyperplasia; lower urinary tract symptoms; quality of life

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO; SILODOSIN; TAMSULOSIN; TERAZOSIN;

AMBLYOPIA; ASTHENIA; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EJACULATION DISORDER; FATIGUE; FLOW RATE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; LIBIDO; LOWER URINARY TRACT SYMPTOM; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; DRUG DESIGN; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 83055176320     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834d9bfd     Document Type: Review

References (56)

1. McNeal JG. The prostate gland: morphology and pathobiology. Monogr Urol 1983; 4:3-33.
2. Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am 2006; 44:689-710. (Pubitemid 44498738)
3. Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153:1510-1515.
4. Lepor H. The pathophysiology of lower urinary tract symptoms in the aging male population. In: Lepor H, editor. Prostatic diseases. Philadelphia, PA:WB Saunders; 2000. pp. 163-196.
5. Jepsen JB, Bruskewitz RC. Clinical manifestations and indications for treatment. In Lepor H, editor. Prostatic diseases. Philadelphia, PA: WB Saunders; 2000. pp. 127-142.
6. McConnell JD, Roehrborn CG, Bautista OM, et al. for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effects of doxazosin, finasteride and the combination on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398. (Pubitemid 37542987)
7. Kaplan SA, McConnell JD, Roehrborn CG, et al. for the MTOPS Research Group. Relationship between prostate size and the effect of combination therapy with doxazosin and finasteride versus either drug alone on the clinical progression of benign prostatic hyperplasia. J Urol 2006; 75:217-221.
8. Barry MJ, Cockett ATK, Holtgrewe HL, et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150:351-358. (Pubitemid 23215869)
9. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150:85-89. (Pubitemid 23175978)
10. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335:533-539. (Pubitemid 26272307)
11. Lepor H. a-Adrenergic blockers for the treatment of benign prostatic hyperplasia. In Lepor H, editor. Prostatic diseases. Philadelphia, PA:WBSaunders; 2000. pp. 297-307.
12. Kaplan SA, Gonzalez RR. Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 2007; 9:73-77.
13. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. J Am Med Assoc 2006; 296:2319-2328. (Pubitemid 44749359)
14. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptom, quality of life and global outcome, and factors predicting response. J Urol 1998; 160:1358-1367. (Pubitemid 29480516)
15. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92:257-261. (Pubitemid 36966589)
16. Bartsch G, Muller HR, Oberholzer M, et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122:487-489.
17. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia as related to the development of clinical BPH. J Urol 1992; 147:1293-1297.
18. Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol 1989; 141:1283-1289. (Pubitemid 19151778)
19. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 27:193-202.
20. Lepor H, Shapiro E. Characterization of the alpha1 adrenergic receptor in human benign prostatic hyperplasia. J Urol 1984; 132:1226-1229. (Pubitemid 15213903)
21. Shapiro E, Lepor H. Alpha2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. J Urol 1986; 135:1038-1042. (Pubitemid 16077246)
22. Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha1 blockade in prostatic hyperplasia. Urology 1988; 32:21-26. (Pubitemid 19013256)
23. Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149:640-642. (Pubitemid 23094076)
24. Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slidemounted tissue section. J Urol 1993; 150:2002-2006. (Pubitemid 24350853)
25. Walden P, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non hyperplastic human prostate. J Urol 1999; 161:635-640.
26. Forray C, Bard JA, Wetzel JM, et al. The alpha1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacologic properties of the cloned human alpha 1c subtype. Mol Pharmacol 1994; 45:703-708.
27. Caine M, Pfau A, Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48:255-263.
28. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50:551-554. (Pubitemid 9073879)
29. Kirby RS, Coppinger SWC, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60:136-142. (Pubitemid 17131826)
30. Martorana G, Giberti C, Damonte P, et al. The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Med Sci 1984; 12:11-12. (Pubitemid 14154818)
31. Lepor H, Auerbach S, Puras-Baez A, et al. A multicenter fixed-dose study of the safety and efficacy of terazosin in the treatment of the symptoms of benign prostatic hyperplasia. J Urol 1992; 148:1467-1474.
32. Brawer MK, Adams G, Epstein H, et al. Terazosin in the treatment of benign prostatic hyperplasic. Arch Fam Med 1993; 2:929-935.
33. Lloyd SN, Buckley JF, Chilton CP, et al. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 1992; 70 (Suppl 1):17-21.
34. Terazosin [package insert]. North Chicago, IL: Abbott Laboratories; 2003.
35. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154:105-109.
36. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled dose response multicenter study. J Urol 1995; 154:110-115.
37. Doxazosin [package insert]. New York, NY: Pfizer Inc.; 2003.
38. Kirby RS. Terazosin in benign prostatic hyperplasia: effect on blood pressure in normotensive and hypertensive men. Br J Urol 1998; 82:373-379. (Pubitemid 28434610)
39. Kirby RS. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46:182-186.
40. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000; 283:1967-1975.
41. Kenny BA, Miller AM, Williamson IJ, et al. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996; 118:871-878. (Pubitemid 26261256)
42. Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol 1994; 45:703-708.
43. Lepor H for the Tamsulosin Investigator Group. Phase III multicenter placebocontrolled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51:892-900.
44. Narayan P, Tewari A. The United States 93-01Study Group: a second phase III multicenter placebo controlled study of 2 doses of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160:1701-1706. (Pubitemid 128746741)
45. Tamsulosin [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2003.
46. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176:1529-1533. (Pubitemid 44307193)
47. Wolters JP, Hellstrom WJ. Current concepts in ejaculatory dysfunction. Rev Urol 2006; 8 (4 Suppl):S18-SS25.
48. Alfuzosin [package insert]. Bridgewater, NJ: Sanofi-Synthelabo Inc.; 2004.
49. Van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37:306-313. (Pubitemid 30122265)
50. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia; a randomized, placebo-controlled trial. Urology 2001; 58:953-959. (Pubitemid 34017278)
51. Roehrborn CG, McConnell JD, Barry MJ and the AUA BPH Guideline Update Panel. Guideline on the management of benign prostatic hyperplasia (BPH). 2003; chapters 1-23. http://www.auanet.org/guidelines/bph.cfm. [Accessed 1 October 2007]
52. Tatemichi S, Kobayashi K, Maezawa A, et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213) Yakugaku Zasshi. 2006; 126 Spec no. pp. 209-216.
53. Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy 2010; 30:1303-1312.
54. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181:2634-2640.
55. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis 2011; 14:143-148.
56. RAPAFLO1(Silodosin) [package insert]. Corona, CA: Watson Laboratories Inc.; 2009.